Category: Latest News

Tail-Engineered Phage P2 for Antimicrobials Delivery

Tail-Engineered Phage P2 for Antimicrobials Delivery

Posted on by Targeting Phage Therapy
    Bacteriophages can be reprogrammed to deliver antimicrobials for therapeutic and biocontrol purposes and are a promising alternative treatment to antimicrobial-resistant bacteria. Fa-arun et al. developed a bacteriophage P4 cosmid system for the delivery of a Cas9 antimicrobial into clinically relevant human gut pathogens Shigella flexneri and Escherichia coli O157:H7.  Their P4 cosmid design…
Posted on February 27, 2023
Read More
Potential for Bacteriophages as Anticancer Agents

Potential for Bacteriophages as Anticancer Agents

Posted on by Targeting Phage Therapy
Press release written by Dr. Swapnil Ganesh Sanmukh. Cancer is one of the leading causes of death worldwide, with prostate cancer (PCa) being the leading cause of death among men globally. As components of the microbiome, including bacteriophages, are considered relevant concerning the diagnostics and therapeutics of malignant diseases, new interest has emerged to identify their…
Posted on February 10, 2023
Read More
Managing phage therapy to help save lives

Managing phage therapy to help save lives

Posted on by Targeting Phage Therapy
Phages are viruses that can infect and kill bacteria without affecting human or animal cells. Phage therapy was used extensively in the early 20th century prior to the use of antibiotics. (Stock illustration) Scientists with the Texas A&M College of Agriculture and Life Sciences were among those providing the biochemical tools needed to help save a man’s…
Posted on January 27, 2023
Read More
Phage trial to treat CF patients with multi-drug resistant bacterial infections

Phage trial to treat CF patients with multi-drug resistant bacterial infections

Posted on by Targeting Phage Therapy
A false-color micrograph depicts phages attacking a bacterium. Thomas Deerinck, National Center for Microscopy and Imaging, UC San Diego Cystic fibrosis (CF) is an inherited disorder that causes severe damage to the lungs and other organs in the body. Nearly 40,000 children and adults in the United States live with CF, an often difficult existence…
Posted on January 27, 2023
Read More
NIH-supported clinical trial of phage therapy for cystic fibrosis begins

NIH-supported clinical trial of phage therapy for cystic fibrosis begins

Posted on by Targeting Phage Therapy
This digitally-colorized scanning electron microscopic (SEM) image shows a number of rod-shaped Pseudomonas aeruginosa bacteria Enrollment has begun in an early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa (P. aeruginosa) in their lungs. The trial is evaluating whether the bacteriophage, or “phage,” therapy is safe and able to reduce…
Posted on January 27, 2023
Read More
A novel virulent Litunavirus phage against multidrug resistant Pseudomonas aeruginosa

A novel virulent Litunavirus phage against multidrug resistant Pseudomonas aeruginosa

Posted on by Targeting Phage Therapy
Transmission electron micrographs of phage VL1 negatively stained with 2% (w/v) uranyl acetate. The scale bar represents 200 nm. Pseudomonas aeruginosa is a notable nosocomial pathogen that can cause severe infections in humans and animals. The emergence of multidrug resistant (MDR) P. aeruginosa has motivated the development of phages to treat the infections. Lerdsittikul et al.…
Posted on January 11, 2023
Read More
Anti-Biofilm Effect of Bacteriophages & Antibiotics against Uropathogenic E. coli

Anti-Biofilm Effect of Bacteriophages & Antibiotics against Uropathogenic E. coli

Posted on by Targeting Phage Therapy
 Pyobacteriophag effect before (1 and 1′) and after (2 and 2′) adaptation to strain 01206UR Escherichia coli is a common cause of biofilm-associated urinary tract infections. Bacteria inside the biofilm are more resistant to antibiotics. In a study by Mukane et al, six E. coli strains isolated from patients with urinary tract infections were screened for biofilm-forming…
Posted on December 13, 2022
Read More
Bacteriophage Cocktails in the Post-COVID Rehabilitation

Bacteriophage Cocktails in the Post-COVID Rehabilitation

Posted on by Targeting Phage Therapy
Increasing evidence suggests that gut dysbiosis is associated with coronavirus disease 2019 (COVID-19) infection and may persist long after disease resolution. The excessive use of antimicrobials in patients with COVID-19 can lead to additional destruction of the microbiota, as well as to the growth and spread of antimicrobial resistance. The problem of bacterial resistance to…
Posted on December 13, 2022
Read More
Zn2+- Releasing Phage Bound to Gold Nanorods for Treating Wound Infections

Zn2+- Releasing Phage Bound to Gold Nanorods for Treating Wound Infections

Posted on by Targeting Phage Therapy
Phage therapy forms a good alternative to antibiotics, but it poses serious drawbacks and safety concerns, such as the risk of genetic transduction of antibiotic resistance genes, inconsistent pharmacokinetics, and unknown evolutionary potential.  Metallic nanoparticles, in turn, possess precise, tunable properties, including efficient conversion of electronic excitation into heat. Peng et al., demonstrated that engineered…
Posted on December 13, 2022
Read More
Engineered Bacteriophages Suppress Antibiotic Resistant P. Aeuruginosa Infection

Engineered Bacteriophages Suppress Antibiotic Resistant P. Aeuruginosa Infection

Posted on by Targeting Phage Therapy
 DMS3acrIF1 mitigates tissue injury and improve survival – histological analysis   The therapeutic use of bacteriophages provides great promise for treating multidrug-resistant (MDR) bacterial infections. However, an incomplete understanding of the interactions between phages and bacteria has negatively impacted the application of phage therapy.   Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic Gram-negative bacterium that causes…
Posted on November 15, 2022
Read More